The contract development and manufacturing organization (CDMO) launched its end-to-end offering for inhalation products under the new business name Recipharm Inhalation Solutions.
The offering will service customers from early stage development through commercial manufacturing as it offers companies outsourced development and manufacturing for inhaled products including metered dose inhalers, dry powder inhalers, and nasal sprays.
Shabbir Mostafa, global key account director of Inhalations at Recipharm, said in a statement that treatments for respiratory conditions are in high demand and inhalation products are an area of growth for the company.
“In addition to respiratory diseases, they [inhalation products] are now being explored as alternative delivery routes to improve bioavailability and lower the risk of adverse effects, in treating, for instance, central nervous system conditions. This is making inhalation an interesting area for drug developers,” Mostafa added.
Recipharm Inhalation Solutions was formed after the company acquired Sanofi’s inhalation manufacturing business in June 2018 in a $60m (₤45m) deal. The business located in Holmes Chapel, UK specialized in the manufacture of inhalation drug products.
Per the acquisition agreement, Recipharm took over existing manufacturing contracts for drugs made on-site, and through a long-term manufacturing agreement to produce key products for Sanofi.
However, the facility that will support Recipharm Inhalation Solutions will be located in the US at Research Triangle Park, North Carolina. The North Carolina plant added a new good manufacturing practice (GMP) suite in 2017 for early development services and manufacture of non-sterile dosage forms including inhalation products.
The facility will be composed of several suites which can replicate the commercial process for the transfer of projects from small scale to large scale productions to work with different devices, combinations, active pharmaceutical ingredients (APIs), and suspension formulations.
Recipharm did not respond to our request for comment.
